Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine plus magnesium sulfate for refractory chronic cluster headache
IRCT20240305061175N1Phase 2Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ketamine and magnesium sulfate in Refractory Chronic Cluster Headache (rCCH), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: Change in headache attack intensity, Change in headache attack frequency and 3 more. Started Apr 2024; status: completed.
02
Drugs
ketaminemagnesium sulfate
03
Conditions
Refractory Chronic Cluster Headache (rCCH)
Beyond the preview
Go deeper on IRCT20240305061175N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240305061175N1.